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and safety of RPC4046 in an open-label, long-term extension (LTE) study in adults with EoE.METHODS: We analyzed data from 66 patients who completed the 16-week, double-blind, induction
portion of a phase 2 study of RPC4046 (180 mg or 360 mg/wk) vs placebo and then completed a
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dex score, £20) increased from 14% at LTE entry to 67% at LTE week 52 in placebo‒RPC4046
patients and from 30% to 54% in RPC4046‒RPC4046 (either dose) patients. Of the 28 patients
who did not have a histologic response to RPC4046 during the double-blind induction phase, 10
patients (36%) achieved response during the LTE. The most common adverse events were
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improvement and/or maintenance of endoscopic, histologic, and clinical measures of EoE dis-
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What You Need to Know
Background
The safety and efficacy of RPC4046 was shown in the
16-week induction period of a phase 2, randomized,
controlled study of adults with symptomatic eosin-
ophilic esophagitis (EoE). This study reports results
from the 52-week, open-label, long-term extension
period.
Findings
Over 52 weeks, RPC4046 resulted in continued
improvement and/or maintenance of endoscopic,
histologic, and clinical measures of EoE activity,
relative to baseline, and was generally well tolerated.
Implications for patient care
Encouraging findings from a study of 1 year or
longer of RPC4046 treatment of patients with
symptomatic EoE support confirmatory studies.
474 Dellon et al Clinical Gastroenterology and Hepatology Vol. 19, No. 3Eosinophilic esophagitis (EoE) is a chronic,allergic/immune-mediated, clinicopathologic dis-
ease of the esophagus characterized histologically by
eosinophil-predominant mucosal inflammation and clini-
cally by signs and symptoms of esophageal dysfunc-
tion.1,2 Complications of EoE, including strictures and
food impaction, are related mostly to esophageal remod-
eling and fibrostenosis and associated with a longer
duration of untreated disease.3,4 Although a topical ste-
roid in orodispersible tablet form5 is approved for EoE
treatment in Europe, there are no approved EoE treat-
ments in the United States. Off-label orally/topically
administered corticosteroids are a mainstay of
therapy,6–12 but their use is limited by side effects,
including candidal esophagitis, oral candidiasis, and
atropy of the esophageal mucosa, and long-term safety
data are limited.13 Moreover, evidence suggests pro-
longed topical corticosteroid use may be only partially
effective in maintaining disease remission14–19 and asso-
ciated with resistance.20
Interleukin 13 (IL13), a pleotropic cytokine involved
in T-helper cell 2–type inflammation, plays an important
role in the pathogenesis of EoE.21 IL13 is overexpressed
in the esophageal mucosa of EoE subjects; it has been
shown to induce a gene transcript profile that overlaps
with the EoE-specific esophageal transcriptome22 and to
modulate cellular and molecular pathways involved in
eosinophil recruitment,23 esophageal barrier function,24
and tissue remodeling and fibrosis.25 Simulated altered
expression/blockade of IL13 in animal models produces
fluctuations in EoE disease status and esophageal
function.25–28 Given the prominent role of IL13 in EoE
pathogenesis, blockade of this cascade is a potential
treatment target.
RPC4046 is a recombinant, humanized, highly selec-
tive, monoclonal (IgG1k) antibody that recognizes the
wild-type and variant human IL13 and inhibits binding
to both IL13-receptor subtypes: IL13Ra1 and IL13Ra2.29
The safety and efficacy of RPC4046 vs placebo were
shown in the induction period of a phase 2, 16-week,
randomized, controlled study in adults with symptomatic
EoE (RPC02-201; ClinicalTrials.gov study ID:
NCT02098473).30 Subjects completing the induction
period then had the option to enroll in a subsequent 52-
week, open-label, long-term extension (LTE) period;
these findings are reported herein.Methods
Trial Design
We conducted an open-label LTE of the phase 2
RPC02-201 study (NCT02098473) after completion of
the 16-week double-blind (DB) period in subjects with
symptomatic EoE. The study was conducted at 28 cen-
ters in 3 countries (Supplementary Table 1), with
enrollment between September 2014 and January 2017and study completion in October 2017. The study was
conducted in accordance with the Declaration of Helsinki
and the Good Clinical Practice Guidelines established by
the International Conference on Harmonization. Pro-
tocols, amendments, and informed consent documenta-
tion were reviewed and approved by the Institutional
Review Boards and/or Independent Ethics Committee of
each study center. All subjects provided informed
consent.
Key inclusion/exclusion criteria have been reported
previously30 and are detailed in the Supplementary
Material. During the initial DB period (16 weeks), sub-
jects received placebo (n ¼ 34), RPC4046 180 mg (n ¼
31), or RPC4046 360 mg (n ¼ 34) subcutaneously once
weekly; 90 subjects completed the DB induction portion
(through week 16). Subjects entering the LTE period
were required to have 80% or greater study drug
compliance and no clinically significant adverse events
(AEs), as deemed by the investigator, that would pre-
clude further dosing. During the LTE, all subjects
received RPC4046 360 mg for 52 additional weeks; the
higher dose was chosen for LTE because at the time of
the study design, the dose-response and efficacy profile
of RPC4046 were not known.
Prior treatment with corticosteroids for EoE was
recorded at the DB baseline. Steroid-refractory status
was defined as an adequate trial of systemic or topical
steroids failing to result in improvements in inflamma-
tion and patient symptoms, as judged by the investigator.
Outcome Measures
Primary efficacy outcome measures included
esophageal eosinophil counts (mean counts [eosin-
ophils per high-power field (hpf); hpf size, 0.3 mm2]
calculated from the 5 most inflamed hpfs from
Table 1. Patient Demographics and Disease Characteristics: LTE Population
Placebo (n ¼ 29)
RPC4046
180 mg (n ¼ 28)
RPC4046 360
mg (n ¼ 29) Total (n ¼ 86)
Age, y
Mean 39.8 (11.02) 38.8 (9.79) 32.8 (9.74) 37.1 (10.56)
Minimum, maximum 21, 64 19, 59 18, 60 18, 64
Sex, n (%)
Male 19 (65.5) 18 (64.3) 19 (65.5) 56 (65.1)
Female 10 (34.5) 10 (35.7) 10 (34.5) 30 (34.9)
Race, n (%)
White 29 (100) 27 (96.4) 29 (100) 85 (98.8)
Black or African American 0 1 (3.6) 0 1 (1.2)
Years since EoE diagnosis
Mean 4.331 (3.003) 4.220 (3.900) 3.711 (2.864) 4.086 (3.253)
Minimum, maximum 0.14, 10.89 0.12, 15.52 0.04, 9.53 0.04, 15.52
Steroid stratification factor, n (%)
Steroid-refractory 14 (48.3) 12 (42.9) 15 (51.7) 41 (47.7)
Not steroid-refractory 15 (51.7) 16 (57.1) 14 (48.3) 45 (52.3)
Baseline eosinophil count/hpf
Mean (SD) 96.93 (54.45) 119.60 (80.80) 125.61 (74.53) 113.98 (70.96)
Minimum, maximum 23.6, 189.8 21.4, 273.0 22.2, 369.2 21.4, 369.2
Baseline peak eosinophil count/hpf
Mean (SD) 111.0 (60.72) 135.4 (88.18) 143.0 (83.67) 129.8 (78.62)
Minimum, maximum 31, 212 24, 304 26, 389 24, 389
LTE baseline eosinophil count/hpfa
Mean (SD) 88.39 (55.87) 27.12 (36.86) 25.61 (30.51) 47.27 (51.35)
Minimum, maximum 12.0, 265.4 0.0, 133.6 0.0, 123.4 0.0, 265.4
LTE baseline peak eosinophil count/hpfa
Mean (SD) 102.6 (63.05) 31.2 (41.55) 31.3 (38.35) 55.3 (59.11)
Minimum, maximum 16, 302 0, 159 0, 157 0, 302
LTE baseline EREFS total score
Mean (SD) 8.1 (5.14) 5.5 (3.83) 6.5 (4.43) 6.7 (4.59)
Minimum, maximum 0, 18 0, 14 0, 18 0, 18
LTE baseline EoEHSS grade score
Mean (SD) 40.9 (13.55) 21.5 (12.41) 20.0 (6.47) 27.5 (14.67)
Minimum, maximum 16.27, 63.49 4.76, 66.87 10.32, 33.33 4.76, 66.87
LTE baseline EoEHSS stage score
Mean (SD) 40.9 (12.69) 21.7 (12.64) 19.4 (6.98) 27.4 (14.66)
Minimum, maximum 17.46, 58.73 1.59, 59.33 9.33, 34.92 1.59, 59.33
LTE baseline EEsAI mean score
Mean (SD) 40.3 (23.36) 37.8 (22.69) 30.1 (25.12) 36.0 (23.88)
Minimum, maximum 0, 78 0, 76 0, 76 0, 78
LTE baseline DSD composite score
Mean (SD) 21.0 (18.55) 20.0 (17.63) 13.8 (16.77) 18.2 (17.66)
Minimum, maximum 0.0, 51.7 0.0, 46.7 0.0, 45.5 0.0, 51.7
DSD, daily symptom diary; EEsAI, Eosinophilic Esophagitis Activity Index; EoE, eosinophilic esophagitis; EoEHSS, Eosinophilic Esophagitis Histologic Scoring
System Score; EREFS, Eosinophilic Esophagitis Endoscopic Reference Score; LTE, long-term extension.
aBaseline was defined as the last observed score before the first dose of study drug during the LTE.
March 2021 Anti-IL13 RPC4046 EoE Trial LTE 475among all esophageal biopsy specimens [proximal,
mid, and distal], peak counts, and peak response
threshold of <15/hpf). Secondary outcome measures
included daily symptom diary (DSD) scores, EoE
Endoscopic Reference Score (EREFS), EoE Histologic
Scoring System (EoEHSS) score, and symptom-based
EoE Symptom Activity Index (EEsAI) score.31–34
Eosinophil counts were quantified centrally by the
study pathologist, who was blinded to treatment allo-
cation. Endoscopic and histologic outcomes were
measured at DB week 16 and at LTE weeks 12, 24, and
52 (additional information can be found in the
Supplementary Methods).Statistical Analysis: Efficacy
Efficacy analyses were conducted in the LTE analysis
population, defined as all subjects receiving at least 1
dose of study drug during the LTE. Results were
analyzed by the original dose group assigned to subjects
during the DB induction period (placebo, RPC4046 180
mg, or RPC4046 360 mg) and presented descriptively.
The LTE baseline was defined as the last observed value
scheduled, before the first dose date during the LTE.
Continuous data were summarized using mean, SD or
SEM, median, minimum, and maximum values. Categoric
data were summarized as the proportions of subjects.
476 Dellon et al Clinical Gastroenterology and Hepatology Vol. 19, No. 3Safety Analyses
No statistical hypothesis testing was performed on
safety results. AEs were described as the raw number of
treatment-emergent AEs (TEAEs), percentages of sub-
jects, and as exposure-adjusted incidence rates per 100
patient-years of exposure. TEAEs were defined as AEs
with onset on or after the first dose of study drug during
the LTE, or AEs that started before the first dose of study
drug during the LTE but worsened on or after the first
dose of study drug during the LTE. Serious AEs (SAEs)
also were assessed.Results
Disposition
Among the 90 subjects who completed the DB
treatment period, 86 were enrolled in the LTE (placebo,Figure 1. Clinical efficacy outcomes. Clinical results for the lon
LTE study entry, week 12, week 24, and week 52. (A) The mea
proportion of subjects achieving a peak esophageal eosinophil
mean total eosinophilic esophagitis endoscopic reference sco
modified scoring system described by Hirano et al31). (D) The
determined by an Eosinophilic Esophagitis Activity Index (EE
extension.n ¼ 29; RPC4046 180 mg, n ¼ 28; and RPC4046 360 mg,
n ¼ 29) (Supplementary Figure 1). Twenty of the 86
subjects (23%) did not complete the full 52-week dura-
tion as part of the LTE. Five of these patients had higher
mean esophageal eosinophil counts before study drug
discontinuation relative to baseline LTE; however, study
discontinuations were not associated with the long-term
efficacy of RPC4046. Reasons for study drug discontin-
uation during the LTE included withdrawal of consent
(n ¼ 7), AE (n ¼ 6), noncompliance (n ¼ 3), other (n ¼
2), investigator decision (n ¼ 1), and pregnancy (n ¼ 1).Demographic and Disease Characteristics
Demographic and disease characteristics of subjects
entering the LTE were consistent with the population
characteristics of the initial DB induction phase of the
trial. Subjects enrolled in the LTE had a mean age of
37.1 years, with a mean of 4.1 years since their EoEg-term extension (LTE) patient group at main study baseline,
n esophageal eosinophil count per high-power field. (B) The
count less than 15 eosinophils per high-power field. (C) The
re (EREFS) (endoscopic findings analyzed according to the
proportion of subjects achieving symptomatic remission as
sAI) score of 20 or less (LTE population). OLE, open-label
Figure 2. Peak eosinophils (EOS) over time (baseline double-blind week 16, long-term extension [LTE] weeks 12, 24, and 52)
by treatment group. (A) Average of individuals within each treatment group: placebo, RPC4046 180 mg, and RPC4046 360 mg.
(B) Individual data from the placebo group. (C) Individual data from the RPC4046 180 mg group. (D) Individual data from the
RPC4046 360 mg group (LTE population). OLE, open-label extension.
March 2021 Anti-IL13 RPC4046 EoE Trial LTE 477diagnosis; approximately 48% were steroid-refractory
(Table 1).Clinical Efficacy
At LTE entry, the mean esophageal eosinophil counts
for subjects previously treated with placebo were sub-
stantially higher than for subjects previously receiving
active treatment (Table 1; Figure 1A); by LTE week 12,
counts had decreased to the levels observed in both
RPC4046 groups, which was maintained through LTE
week 52 (Figure 1A). Similarly, at LTE entry, peak
esophageal eosinophil counts in subjects previously
treated with placebo were 3-fold greater than in subjects
previously receiving active treatment (Table 1); these
counts had decreased to levels observed in both
RPC4046 groups by LTE week 12, which was maintained
through LTE week 52 (Figure 2A). No effect of RPC4046
on the mean absolute blood eosinophil levels was
observed at LTE week 52 (Supplementary Table 2). The
proportion of responders (peak esophageal eosinophil
count, <15 hpf) increased from LTE week 12 to LTE
week 52 in all 3 groups (placebo, 28.6% [week 12] to
57.1% [week 52]; RPC4046 180 mg, 53.6% to 73.9%;
RPC4046 360 mg, 44.4% to 59.1%) (Figure 1B).The EREFS total and composite (inflammation and
remodeling) scores over all locations decreased from
LTE baseline through LTE week 52 in subjects previously
randomized to placebo; in those previously receiving
active treatment during the DB induction phase, further
improvement beyond the LTE baseline was seen at both
week 12 and week 52 (Figures 1C and 3A–C). At LTE
week 52, decreases in EREFS scores were numerically
greater in subjects previously treated with placebo vs
RPC4046 (mean change from LTE baseline to week 52
for placebo, -5.0; for RPC4046 180 mg, -1.3; and for
RPC4046 360 mg, -2.9). EREFS individual components
scores over all locations (Supplementary Table 3) and
EREFS components by location (data not shown) were
similar across groups throughout the LTE period. EREFS
total scores over time in individual subjects are shown in
Supplementary Figure 2.
EoEHSS grade scores for subjects previously treated
with placebo were 2-fold greater than for subjects pre-
viously treated with RPC4046 (either dose) at LTE entry
(Table 1). By LTE week 52, EoEHSS grade scores had
decreased substantially for subjects previously treated
with placebo (mean change from LTE baseline to week
52 for placebo, -21.5; for RPC4046 180 mg, -2.9; and for
RPC4046 360 mg, 2.1) (Figure 3D). The mean absolute
EoEHSS grade scores were similar across the treatment
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Table 2. Peak EOS Count Responder Analysis: Observed Cases in the LTE Population
Randomized treatment assignment at DB baseline
RPC4046




180 mg (n ¼ 28)
RPC4046
360 mg (n ¼ 29)
Proportion of patients with response at DB week 16, n/N (%)
Peak EOS <15 at DB week 16 0/29 (0) 14/28 (50.0) 15/29 (51.7) 29/57 (50.9)
Peak EOS 15 at DB week 16 29/29 (100) 14/28 (50.0) 14/29 (49.3) 28/57 (49.1)
Proportion of patients with response at DB week 16 and LTE week 52, n/N (%)
Peak EOS <15 at DB week 16 and peak EOS <15 at
LTE seek 52a
0/0 (0) 10/14 (71.4) 10/15 (66.7) 20/29 (69.0)
Peak EOS <15 at DB week 16 and peak EOS 15 at
LTE week 52a
0/0 (0) 1/14 (7.1) 2/15 (13.3) 3/29 (10.3)
Peak EOS 15 at DB week 16 and peak EOS <15 at
LTE week 52b
12/29 (41.4) 7/14 (50.0) 3/14 (21.4) 10/28 (35.7)
Peak EOS 15 at DB week 16 and peak EOS 15 at
LTE week 52b
9/29 (31.0) 5/14 (35.7) 7/14 (50.0) 12/28 (42.9)
DB, double blind; EOS, eosinophilic esophagitis; LTE, long-term extension.
aDenominator is the number of subjects with a peak EOS less than 15 at DB week 16.
bDenominator is the number of subjects with a peak EOS of 15 or higher at DB week 16.
March 2021 Anti-IL13 RPC4046 EoE Trial LTE 479groups at LTE week 52 (19.9, 19.5, and 21.9, respec-
tively). At LTE entry, the EoEHSS stage scores for sub-
jects previously treated with placebo were 2-fold greater
than for subjects previously receiving active treatment.
By LTE week 52, scores for subjects previously treated
with placebo had decreased (mean change from LTE
baseline to week 52 for placebo, -20.8; for RPC4046 180
mg, -1.9; and for RPC4046 360 mg, 3.5) (Figure 3E), and
the mean absolute values generally were similar to those
in both RPC4046 groups (20.4, 21.4, and 22.2,
respectively).
The EEsAI mean (SD) scores for the placebo,
RPC4046 180 mg, and RPC4046 360 mg groups
improved from LTE baseline through LTE week 12
(mean change: placebo, -9.1; RPC4046 180 mg, -9.1; and
RPC4046 360 mg, -8.7) and from LTE baseline through
LTE week 52 (mean change: placebo, -21.1; RPC4046
180 mg, -10.6; and RPC4046 360 mg, -14.6). The pro-
portion of subjects achieving symptomatic remission
(EEsAI score, 20) showed a similar trend of increase in
all treatment groups from LTE baseline through LTE
week 52 (Figure 1D). The proportion of subjects
achieving EEsAI remission increased in the placebo
(13.8% [LTE baseline] to 66.7% [LTE week 52]),
RPC4046 180 mg (25.0% to 41.7%), and RPC4046 360
mg (34.5% to 68.2%) groups (Supplementary Table 4).
EEsAI scores over time in individual subjects are shown
in Supplementary Figure 3. At LTE entry, the mean DSD
composite score in subjects previously treated with
RPC4046 360 mg were lower than in subjects previously
treated with placebo or RPC4046 180 mg. By LTE week=
Figure 3.Mean (SEM) changes from long-term extension (LT
Esophagitis Endoscopic Reference Score (EREFS) (total, inflam
tologic Scoring System Score (EoEHSS) grade and stage score
score. (C) EREFS remodeling composite score. (D) EoEHSS gra52, scores for all groups had decreased (mean change:
placebo, -8.61; RPC4046 180 mg, -11.31; and RPC4046
360 mg, -8.46) (Supplementary Table 5).
Further post hoc analysis assessed whether peak
esophageal eosinophil count response achieved with
randomized treatment by week 16 of the DB induction
period was maintained at week 52 with RPC4046 360-
mg treatment (Table 2). A majority of the subjects
(69.0%) who had a histologic response at DB week 16
with active treatment (RPC4046 180 mg or 360 mg)
maintained it at LTE week 52 (20 of 29); 10.3% (3 of
29) lost prior response. Among subjects entering LTE
who were not histologic responders (peak eosinophil
counts, 15 hpf) after 16 weeks of active study drug
treatment during the DB induction phase (n ¼ 28), 10
(35.7%) subjects (RPC4046 180 mg, n ¼ 7; RPC4046
360 mg, n ¼ 3) were able to achieve histologic
response with RPC4046 360 mg at LTE week 52
(Table 2; Figure 2C and D).
Steroid-Refractory Vs Non–Steroid-Refractory
Subjects
Forty-one of 86 subjects enrolled in the LTE study
were considered steroid-refractory. No notable differ-
ences were observed between the steroid-refractory and
non–steroid-refractory groups for mean changes from
LTE entry over the LTE period in mean esophageal
eosinophil counts (Supplementary Figure 4A and B), DSD
composite scores and components (Supplementary
Figure 4C and D), EREFS total score (SupplementaryE) baseline to LTE weeks 12, 24, and 52 for Eosinophilic
mation, and remodeling), and Eosinophilic Esophagitis His-
s. (A) EREFS total score. (B) EREFS inflammation composite
de score. (E) EoEHSS stage score (LTE population).
Table 3. Summary of Safety Findings by Study Group During the LTE Period: LTE Population
Randomized treatment assignment at DB
baseline




180 mg (n ¼ 28)
RPC4046
360 mg (n ¼ 29)
Subject with 1 TEAE, n (%) 21 (72.4) 26 (92.9) 24 (82.8) 71 (82.6)
Subject with 1 possible, probable, or related TEAE,a n (%) 8 (27.6) 13 (46.4) 14 (48.3) 35 (40.7)
Subject with TEAE by maximum severity,b n (%)
Mild 12 (41.4) 11 (39.3) 10 (34.5) 33 (38.4)
Moderate 6 (20.7) 11 (39.3) 9 (31.0) 26 (30.2)
Severe 3 (10.3) 4 (14.3) 5 (17.2) 12 (14.0)
Subject with 1 serious TEAE,c n (%) 0 2 (7.1) 4 (13.8) 6 (7.0)
Subject with TEAE leading to study drug discontinuation,d n (%) 3 (10.3) 1 (3.6) 2 (6.9) 6 (7.0)
Subject with TEAE leading to withdrawal from study,d n (%) 0 0 1 (3.4) 1 (1.2)
Most frequent TEAE (10% of subjects), n (%) [EAIR/100 PYE]
Upper respiratory tract infection 9 (31.0) [38.8] 6 (21.4) [23.3] 3 (10.3) [12.5] 18 (20.9) [24.7]
Nasopharyngitis 1 (3.4) [4.3] 3 (10.7) [11.6] 8 (27.6) [33.3] 12 (14.0) [16.4]
Oropharyngeal pain 1 (3.4) [4.3] 7 (25.0) [27.2] 2 (6.9) [8.3] 10 (11.6) [13.7]
Sinusitis 2 (6.9) [8.6] 2 (7.1) [7.8] 6 (20.7) [24.9] 10 (11.6) [13.7]
Headache 3 (10.3) [12.9] 4 (14.3) [15.5] 2 (6.9) [8.3] 9 (10.5) [12.3]
Injection site reactions, n (%) [EAIR/100 PYE]
Any injection site reaction 3 (10.3) 6 (21.4) 7 (24.1) 16 (18.6)
Injection site erythema 1 (3.4) [4.3] 1 (3.6) [3.9] 2 (6.9) [8.3] 4 (4.7) [5.5]
Injection site hematoma 1 (3.4) [4.3] 1 (3.6) [3.9] 2 (6.9) [8.3] 4 (4.7) [5.5]
DB, double-blind; EAIR, exposure-adjusted incidence rate; LTE, long-term extension; PYE, patient-years of exposure; TEAE, treatment-emergent adverse event.
aSubjects reporting more than 1 TEAE were counted only once using the closest relationship to study drug.
bSubjects reporting more than 1 TEAE were counted only once using the highest severity.
cSerious adverse events included unlikely or not related to study drug (acute asthma exacerbation, schizophrenia, diverticulitis with microperforation, right femur
fracture [motorcycle accident]) and possibly related (acute cholecystitis, spontaneous abortion).
dBecause of how data were captured on the disposition electronic case report form, only 1 subject was reported to have TEAEs leading to withdrawal from the
study. However, the 6 subjects who discontinued study drug because of TEAEs also withdrew from the study.
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Results: Steroid-Refractory and Non-Steroid Refractory
Subjects for detailed results).Atopic Subjects
Sixty-one of 90 (67.8 %) subjects who completed the
DB induction period had a history of atopy/allergies at
baseline, of whom 45 received active study drug. Forty-
three of 60 atopic subjects from the DB period
completed 52 weeks of LTE treatment. Overall, no
marked differences in histologic response
(Supplementary Table 6), endoscopic (EREFS;
Supplementary Table 7), or symptom scores (EEsAI
remission score, 20) (Supplementary Table 4) were
observed in atopic subjects vs the overall study popula-
tion after long-term treatment with RPC4046 360 mg. No
significant impact on IgE levels was observed in atopic
patients or the overall study population.Safety Assessments
Generally, RPC4046 was well tolerated; the majority
of AEs reported in the LTE period were consistent with
those in the induction period, with no new clinicallysignificant AEs identified with longer-term treatment.
Overall, the majority of subjects with TEAEs had TEAEs
of mild or moderate severity (83.1%). Seventy-one sub-
jects (82.6%) reported 1 or more TEAEs; 6 subjects (7%)
reported 1 or more SAEs (Table 3; Supplementary
Table 8). All SAEs with the exception of the case of
schizophrenia were resolved by the end of the study. The
most commonly reported TEAEs (10%) were an upper
respiratory tract infection in 18 subjects, nasopharyngitis
in 12 subjects, sinusitis and oropharyngeal pain in 10
subjects each, and headache in 9 subjects (Table 3). In-
jection site reaction was reported in 18.6% of subjects in
the LTE period, with injection-site erythema and hema-
toma occurring in 4 subjects (4.7%) (5.5 exposure-
adjusted incidence rate/100 patient-years of exposure)
each (Supplementary Table 9). Of note, there were no
significant changes in blood eosinophils from baseline to
week 52 in the LTE population (Supplementary Table 2).
Increased blood eosinophil levels (1000 cells/mL) were
observed in 11 subjects during LTE, including baseline,
that were mostly transitory or observed at single time
points; none were greater than 2100 cells/mL. No TEAEs
were attributed to increases in blood eosinophil counts.
The incidence of immunogenicity was low; only 4
subjects tested positive for antidrug antibody (ADA)
across the DB and LTE periods. Two subjects, both in the
March 2021 Anti-IL13 RPC4046 EoE Trial LTE 481RPC4046 180 mg group, tested positive for ADA during
the DB period, 1 of whom was only ADA (þ) at DB day 1
(predose) and DB week 12; the other subject was ADA
(þ) at DB weeks 12 and 16 and LTE weeks 2, 4, and 12,
but ADA (-) at subsequent LTE visits. Two additional
subjects in the DB randomized placebo group were ADA
(þ) during LTE, 1 at LTE week 24 only and the other at
LTE weeks 12, 24, and 52 (additional details are pro-
vided in the Supplementary Materials Immunogenicity
Assessment). The potential impact of immunogenicity on
RPC4046 cannot be characterized because only a few
subjects had ADAs during the trial period.Discussion
Targeted EoE immunotherapies present a potential
treatment option for the significant numbers of patients
who are refractory to current therapies.35 Several biologic
monoclonal antibodies have been evaluated,36 but long-
term data are limited.37 In the DB randomized, placebo-
controlled portion of this phase 2 trial, the novel anti-
IL13 monoclonal antibody RPC4046 showed efficacy as
a targeted therapeutic option in EoE patients.30 We report
several notable findings in the open-label LTE portion of
this trial. Overall, subjects initially treated with RPC4046
(180 mg and 360 mg) in the DB phase had continued
endoscopic, histologic, and clinical improvement of EoE
disease activity for an additional 52weeks. Improvements
were shown by continued reductions in the mean and
peak esophageal eosinophil count, stable histologic scores
as determined by EoEHSS, and continued improvement in
mucosal appearance by EREFS. Moreover, subjects who
initially received placebo experienced improvements as
early as the LTEweek 12 visit, despite not having received
an intravenous RPC4046 loading dose; these improve-
ments were maintained for the remaining LTE period.
Subjects who received RPC4046 180 mg during the DB
period did not show significant differences in improve-
ment when given an increased dose of 360 mg RPC4046
during LTE, indicating a consistent long-term effect of
RPC4046. Importantly, similar responses were seen in the
non–steroid-refractory subgroup and the difficult-to-treat
steroid-refractory subgroup (a group with no current
pharmacologic options who would be well-suited to bio-
logic therapy). Although not all patients reached pre-
defined peak esophageal eosinophil values defining
treatment response, most patients showed notable de-
creases in peak eosinophil counts throughout the long-
term treatment period relative to baseline.
RPC4046 was well tolerated with little immunoge-
nicity elicited in the LTE period. Overall, the majority of
TEAEs were mild or moderate in severity. No deaths
occurred during the LTE, and only 2 SAEs were assessed
as possibly related to the study drug (cholecystitis and
spontaneous abortion), which resolved by study end.
The current open-label LTE portion of this phase 2
study includes long prospective LTE follow-up studies inEOE patients, providing long-term data on biologic
treatment in EoE using validated outcome measures. A
potential limitation is that approximately 25% (20 of 86)
of subjects were not able to complete the full 52-week
LTE duration. The LTE portion of the study was open-
label in design and thus not blinded, which limited the
ability to conduct statistical comparisons. Symptom data,
in particular, should be interpreted with caution because
patients knew they were receiving an active medication;
however, changes in symptom data were similar in the
DB and LTE periods. Evaluation of only RPC4046 360 mg
in the LTE period is another potential limitation; how-
ever, the safety and immunogenicity data suggest that
this dose was well tolerated, with no new safety signals
identified with longer-term treatment. Finally, the cur-
rent study was not stratified by EoE endotype; therefore,
evaluation of RPC4046 in patients with distinct EoE
endotypes38 remains an area for further exploration.
The current study showed no significant safety con-
cerns in subjects receiving RPC4046 for 52 weeks and
beyond. Subjects in the LTE period had clinical, endo-
scopic, and histologic improvement of EoE relative to
baseline; those who switched from placebo to RPC4046
showed clinical disease improvement as early as 12
weeks. Subgroup analyses further suggest efficacy in
both the steroid-refractory and non–steroid-refractory
populations. These data support further confirmatory
studies of RPC4046.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2020.03.036.References
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Study Investigators
The study investigators at the initiated sites were as
follows: Canada: Fergal Donnellan, Gastrointestinal
Research Unit, The Gordon and Leslie Diamond Centre,
Vancouver Hospital; Marietta Iacucci, Gastrointestinal
Research Group, University of Calgary Health; and Wil-
liam Paterson, Hotel Dieu Hospital; Switzerland: Alain
Schoepfer, Centre Hospitalier Universitaire Vaudois, and
Alex Straumann, Swiss EoE Clinic; United States: Pablo
Abonia, Cincinnati Children’s Hospital Medical Center;
Yehudith Assouline-Dayan, University of Iowa Hospitals
and Clinics; Kamran Ayub, Southwest Gastroenterology;
Allan Coates, West Michigan Clinical Research Center,
Gastroenterology Associates of Western Michigan; Sid-
ney Cohen, Thomas Jefferson University; Evan Dellon,
University of North Carolina; Taddese Desta, Precision
Research Institute, LLC; Larry Evans, Grand Teton
Research Group; Gary Falk, The University of Pennsyl-
vania; Steven Fein, Digestive Health Center; Nielsen
Fernandez-Becker, Stanford University; David Fleischer,
Children’s Hospital Colorado; Keith Friedenberg, Great
Lakes Gastroenterology Research; Fayez Ghishan, The
University of Arizona Clinical and Translational Science;
Sarah Glover, University of Florida; Gary Goldstein, Vi-
sions Clinical Research; Vikram Gopal, Borland-Groover
Clinic; Craig Gross, Desert Sun Clinical Research, LLC;
Robert Hardi, Metropolitan Gastroenterology Group
Chevy Chase Clinical Research; Ikuo Hirano, North-
western University; Subra Kugathasan, Emory Univer-
sity; Brian Lacy, Dartmouth-Hitchcock Medical Center;
Jeffery Lewis, Children’s Center for Digestive Healthcare;
Paul Menard-Katcher, University of Colorado Anschutz
Medical Center; Benjamin Mitlyng, Minnesota Gastroen-
terology; Fouad Moawad, Walter Reed Army Medical
Center; Rodney Perez, Asheville Gastroenterology Asso-
ciates; Kathryn Peterson, University of Utah; Francisco
Ramirez, Clinical Studies Unit, Mayo Clinic Arizona;
Vonda Reeves-Darby, Gastrointestinal Associates; Ron
Schey, Temple University Hospital; Javaid Shad, Alliance
Clinical Research; Michael Vaezi, Vanderbilt University
Medical Center; John Wo, Indiana University; and Salam
Zakko, Connecticut Clinical Research Foundation.
Note that the 40 listed sites were initiated for
participation in this study; of these sites, 30 enrolled at
least 1 subject.Study Administration
The study administration was as follows: the mem-
bers of the Phase 2, Multi-Center, Multi-national,
Randomized, Double-blind, Placebo-controlled Parallel-
group Clinical Trial to Evaluate the Efficacy and Safety of
RPC4046 in Adult Subjects With Eosinophilic Esophagitis
protocol committee designed the trial in collaborationwith Celgene. Study data were collected by a contract
research organization (Agility Clinical, Inc, Carlsbad, CA)
and analyzed by Celgene. Celgene and the Phase 2,
Multi-Center, Multi-national, Randomized, Double-blind,
Placebo-controlled Parallel-group Clinical Trial to Eval-
uate the Efficacy and Safety of RPC4046 in Adult Subjects
With Eosinophilic Esophagitis study group interpreted
the data jointly and safety data were reviewed by a
safety review. All authors had full access to the data. The
first author wrote the first draft of the manuscript, and
all authors contributed to subsequent drafts, made a
collective decision to submit the manuscript for publi-
cation, and vouch for the completeness and veracity of
the data and analyses and for the adherence to the
protocol, available at NEJM.org. Editorial support was
provided by Celgene. Confidentiality agreements were in
place between Celgene and all authors.
The Protocol Committee included the following: Evan
S. Dellon, MD, MPH (University of North Carolina School
of Medicine, Chapel Hill, NC); Ikuo Hirano, MD (Division
of Gastroenterology, Northwestern University Feinberg
School of Medicine, Chicago, IL); Alex Straumann, MD
(Swiss EoE Clinic, Olten, Switzerland); and Alain M.
Schoepfer, MD (Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland).
The Safety Review Committee included the following:
Sandeep Gupta, MD (Pediatrics and Internal Medicine,
University of Illinois College of Medicine, Peoria, IL); and
Paul Frohna, MD, PhD, PharmD, and Michael Grimm, MD
(formerly with Receptos, a wholly owned subsidiary of
Celgene, Inc, San Diego, CA).Inclusion Criteria
As part of the initial phase 2 study, subjects were
required to be 18 to 65 years of age with a confirmed
diagnosis of EoE. Subjects were required to have symp-
toms of dysphagia for a minimum of 4 days over 2 weeks
(within the 4-week screening period) and histologic ev-
idence of EoE, defined as a peak count of 15 or more
eosinophils per hpf (microscope hpf, 0.3 mm2) at any 2
of 3 levels of the esophagus (proximal, mid, distal) when
off anti-inflammatory therapy for EoE. Subjects must
have previously received an adequate trial of a proton
pump inhibitor and been confirmed to not have proton
pump inhibitor–responsive EoE. Subjects with a partial
response to a proton pump inhibitor who met all other
eligibility criteria could be enrolled; prospective subjects
who discontinued use of a proton pump inhibitor had to
wait at least 4 weeks before their screening endoscopy; if
a prospective subject was receiving a proton pump in-
hibitor at screening, they must have been receiving a
stable dose for at least 4 weeks before the screening
endoscopy and agreed to continue on a the same dose
through week 16; males and females of childbearing
potential had to agree to use adequate birth control
measures during the trial and for 5 months after their
March 2021 Anti-IL13 RPC4046 EoE Trial LTE 483.e2last dose of study drug; and all females of childbearing
potential must have had a negative serum pregnancy test
at screening and a negative urine (or serum) pregnancy
test before dosing on day 1.
Patients who completed the double-blind treatment
period of the phase 2 study, who showed 80% or better
study drug compliance, and who had no clinically sig-
nificant adverse events during initial therapy the were
eligible to be enrolled in the LTE period.Exclusion Criteria
Exclusion criteria included clinical or endoscopic evi-
dence of the presence of any other disease that may have
interfered with or affected the histologic, endoscopic, and
clinical symptom end points for this trial (eg, erosive
esophagitis grade 2 or higher, Barrett’s esophagus, upper
gastrointestinal bleed, eosinophilic gastritis or gastroen-
teritis, active Helicobacter pylori infection, duodenal or
gastric eosinophilia on screening endoscopy, inflamma-
tory bowel disease, significant hiatal hernia [>3 cm]);
presence of esophageal varices; evidence of severe
endoscopic structural abnormality in the esophagus (eg,
high-grade stenosis in which an 8- to 10-mm endoscope
could not pass through the stricture without dilation at
the time of endoscopy); primary causes of esophageal
eosinophilia other than EoE; evidence of immunosup-
pression or were receiving systemic immunosuppressive
or immunomodulating drugs (eg, methotrexate, cyclo-
sporine, interferon a, tumor necrosis factor a inhibitors,
antibodies to IgE, and so forth) within 5 drug half-lives
before screening; were receiving systemic or swallowed
topical corticosteroid medication; prospective subjects
with EoE treated with a corticosteroid must not have
received a systemic corticosteroid within 8 weeks or
swallowed topical corticosteroids within 4 weeks of the
screening endoscopy or the start of the daily clinical
symptom diary data collection during screening, which-
ever was performed first; presence of any other disease
making conduct of the protocol or interpretation of the
trial results difficult or that would have put the prospec-
tive subject at risk by participating in the trial (eg, infec-
tion causing eosinophilia, gastritis, colitis, irritable bowel
syndrome, and celiac disease, which have similar symp-
toms, neurologic or psychiatric illness that compromised
the prospective subject’s ability to accurately document
symptoms of EoE, and so forth); liver function impairment
or persisting increases of aspartate aminotransferase or
alanine aminotransferase greater than 2 times the upper
limit of normal, or direct bilirubin level greater than 1.5
times the upper limit of normal; systemic or diarrheal
illness after travel or residence in endemic areas of
parasitic/helminthic infections, history of clinical schis-
tosomiasis, history of travel to endemic areas within the
preceding 6 months; ongoing infection (eg., hepatitis B or
C, human immunodeficiency virus, active tuberculosis);
pregnancy or lactation; concurrent treatment withanother investigational drug; prospective subjects could
not have participated in a concurrent investigational drug
trial or have received an investigational drug within 5
drug half-lives before signing the informed consent form
for this trial; weight of less than 40 kg (88.2 pounds) or
more than 125 kg (275 pounds); history of idiopathic
anaphylaxis or a known history of a major immunologic
reaction (such as anaphylactic reaction, anaphylactoid
reaction, or serum sickness) to an IgG-containing agent;
history of cancer or lymphoproliferative disease, other
than a successfully treated nonmetastatic cutaneous
squamous cell or basal cell carcinoma or adequately
treated cervical carcinoma in situ, within 10 years of
screening; or esophageal dilation for symptom relief
during the screening period andwithin 4weeks before the
baseline assessment of dysphagia or anticipated to be
performed during the trial.Protocol Amendments
The original protocol (dated March 13, 2014) was
amended 3 times. The first amendment (dated May 16,
2014) was implemented before enrollment of the first
patient in the study (September 3, 2014). Summaries of the
major changes included in each amendment are provided.
Protocol amendment 1: May 16, 2014. The following
amendments were made to the protocol. The LTE was
removed to shorten the total duration of treatment to 16
weeks to be consistent with the available toxicology data
at that time, with the potential to add an LTE after
completion of a then ongoing longer-term toxicology
study. The duration of double-blind dosing was extended
from 12 weeks to 16 weeks, with the longer duration of
double-blind treatment expected to have a greater impact
on eosinophil count and increased clinical benefit. The
time point for efficacy end points was changed from week
12 toweek 16 to be consistent with the increased duration
of double-blind treatment. A week 2 visit was added to
assess ADA and pharmacokinetic data to provide an
earlier time point for these assessments. The lower limit
of the eligible age rangewas increased from 12 years to 18
years to address concerns about adolescents potentially
receiving placebo and being exposed to more than mini-
mal risk. The lower weight limit was increased to 40 kg in
alignment with removal of adolescents from the trial. An
exclusion criterion was added for subjects requiring
esophageal dilation for symptom relief within 4 weeks
before baseline assessment of dysphagia or anticipated to
be performed during the trial; this change was made
because use of esophageal dilation could ameliorate
strictures in symptomatic subjects and therefore would
confound efficacy assessment in this trial. The number of
biomarkers to be assessed was reduced. The restriction
for concurrent medication to treat asthma or allergies
during the trial was modified to enable the investigator to
contact the Medical Monitor to discuss treatment options
if changes to treatments were required, providing more
483.e3 Dellon et al Clinical Gastroenterology and Hepatology Vol. 19, No. 3flexibility for the physician to treat without withdrawal of
the subject.
Protocol amendment 2: October 17, 2014. The
following amendments were made to the protocol. Data
from nonclinical toxicology studies were updated to
report that no observed adverse effects levels were
established at the highest dose evaluated in general
toxicology studies in rats and cynomolgus monkeys and
that once-weekly subcutaneous injections of 20, 60, or
300 mg/kg RPC4046 or intravenous administration of
300 mg/kg RPC4046 for 26 consecutive weeks (26 total
doses) to cynomolgus monkeys was well tolerated at all
dose levels. Treatment was extended by an optional 24-
week LTE. The esophageal string test was removed
because of the limited availability of the test. A require-
ment was specified for collection of DSD for the last 2
consecutive weeks (3 days) before day 1. Text was
added regarding the day 1 intravenous loading dose þ
the subcutaneous dose, and subcutaneous doses once
weekly for 15 additional weeks to avoid confusion
regarding the number of weekly subcutaneous doses to
be administered in the double-blind treatment period.
Modified inclusion criteria were as follows: criterion 1:
clarification that diagnosis of EoE must be confirmed
before randomization; criterion 3: clarification that his-
tologic evidence of EoE can come from any 2 levels of the
esophagus; criterion 5: requirement for birth control use
for 5 months after the last dose of RPC4046 to coincide
with elimination or clearance of the half-life of RPC4046
clearance (ie, 5 times the half-life of 1 month). Additional
modified exclusion criteria were as follows: criterion 10:
specification that ongoing infections include active
tuberculosis; and criterion 15: no history of cancer
within 10 years of screening. The following changes also
were made: changed the intravenous stability dose to 8
hours at 2C to 8C; clarified the food restriction diet and
added instruction regarding environmental therapy;
clarified the requirement not to use systemic or swal-
lowed topical corticosteroids; specified that the blind in
the trial was not to be broken until all subjects
completed the double-blind treatment period (unless
medically necessary); added a coagulation panel during
each hematology and chemistry assessment; extended
the period of AE collection to 30 days after the last dose
or last visit; and added text to clearly define the
intention-to-treat and per-protocol populations.
Protocol amendment 3: June 22, 2015. The following
amendments were made to the protocol: extended the
LTE from 24 weeks to 52 weeks, and removed the
interim analysis from the protocol.Supplementary Methods
Weekly Study Dose
After day 1, dosing with two 1.2-mL subcutaneous
injections of study drug continued weekly through week15. During the LTE period, all subjects were treated with
RPC4046 360 mg subcutaneously.
Immunogenicity Assessment
Double-blind treatment period and long-term extension
period. A validated electrochemiluminescence-based
assay was used to measure the ADA response. A pre-
liminary assessment was performed of the presence of
neutralizing ADA through comparison of RPC4046
pharmacokinetics in ADA-positive and ADA-negative
subjects.
The majority of subjects were ADA-negative at all
visits. Two subjects, both in the RPC4046 180-mg group,
tested positive for ADA during the study.
One subject was ADA-positive on day 1 and at week
12 and was ADA-negative at weeks 2, 4, 8, and 16. This
subject had a mild TEAE of injection site pain (verbatim
term: burning at all injection sites) on day 1 that was
assessed as possibly related to the study drug and had an
unknown outcome. No other TEAEs were reported.
One subject was ADA-negative at all visits from day 1
through week 8 and was ADA-positive at weeks 12 and
16. This subject had the following TEAEs during the
study: mild TEAE of feeling hot (verbatim term: feeling
hot – no fever, no flushing, no sweating) assessed as
probably related to the study drug (day 1); 2 TEAEs of
upper respiratory tract infection, 1 mild and unrelated
(days 3–8) and 1 moderate and possibly related to the
study drug (days 25–36); a mild TEAE of gastroenteritis
that was unlikely related to the study drug (day 32); and
a mild TEAE of nasopharyngitis that was unlikely related
to the study drug (days 99–108). After enrollment into
the LTE, this subject was ADA-positive at LTE weeks 2, 4,
and 12. The subject subsequently was ADA-negative at
LTE weeks 24 and 52, and at the LTE week 60 safety
follow-up visit. The subject had the following TEAEs, all
assessed as unlikely related to the study drug, during the
LTE; mild gastroenteritis (LTE days 83–85); mild
depression (LTE day 110–ongoing); 2 TEAEs of upper
respiratory tract infection, 1 moderate (LTE days
236–270) and 1 mild (days 301–308); and moderate
sinusitis (LTE days 253–270).
Long-term extension period only. One subject was
ADA-negative at all visits during the double-blind treat-
ment period from day 1 (predose) through week 16 and
during the LTE at weeks 2, 4, and 12. The subject tested
positive for ADA at LTE week 24 and subsequently was
ADA-negative at LTE week 52 and at the LTE week 60
safety follow-up visit. The subject had the following
TEAEs during the LTE: severe viral gastroenteritis (LTE
days 10–13) assessed as possibly related to the study
drug; moderate upper respiratory tract infection (LTE
days 82–87) assessed as possibly related to the study
drug; moderate influenza (LTE days 84–87) assessed as
unrelated to the study drug; moderate arthralgia (LTE
147–162) assessed as possibly related to the study drug;
2 TEAEs of mild nausea (LTE days 179 and 366)
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vomiting (LTE days 179 and 366) assessed as unrelated
to the study drug; and mild discolored feces (LTE days
189–200) assessed as unrelated to the study drug.
One subject was ADA-negative at all visits during the
double-blind treatment period from day 1 (predose)
through week 16 and during the LTE at weeks 2 and 4.
The subject tested positive for ADA at LTE weeks 12, 24,
and 52. The only TEAE reported for this subject during
the LTE was a mild event of a headache (LTE day 71)
assessed as unrelated to the study drug.
No subjects in the RPC4046 360-mg group were ADA-
positive at any time during the trial.Antidrug Antibody Assessments
Serum samples to assess blood levels of antibodies to
RPC4046 were obtained predose: on day 1; at weeks 4, 8
and 12 during double-blind treatment; at week 20 (for
subjects who do not continue dosing in the LTE); at LTE
weeks 4, 12, 24, and 32 (for subjects participating in the
LTE); and at early termination.
If ADAs were detected, they were characterized
further as to whether the ADAs were neutralizing or not
in nature. Subjects testing positive for neutralizing anti-
bodies were monitored until the antibody levels return
to baseline.Eosinophilic Esophagitis Activity Index
The EEsAI is a paper-based, patient-reported
outcome symptom instrument that assesses changes in
dysphagia caused by foods of various consistencies,
behavioral adaptations to living with EoE, and
swallowing-associated pain. The EEsAI uses a 7-day
recall period. Based on the summation of individual
scores for EEsAI categories, a total score between 0 and
100 is possible. The mean change from baseline to week
16 in the dysphagia clinical symptoms frequency and
severity as assessed by the EEsAI was a secondary end
point.Composite Daily Symptom Diary Score
The DSD was completed daily for 2 weeks before LTE
baseline (ie, 2 weeks before the week-16 visit of the
double-blind treatment period); 2 weeks before LTE
weeks 12, 24, and 52; and 2 weeks before the LTE week-
60 safety follow-up visit.Daily Symptom Diary Questions
An interactive web-based or telephone response
system was used by subjects to complete a DSD. Subjects
were able to access the diary by telephone and/or by
internet.The following questions were included in the daily
symptom diary:
 Question 1: Did you try to eat solid food today?
 Yes (go to Question 2).
 No (go to Question 1a).
 Question 1a: What is the primary reason you did not
try to eat solid food today?
EoE symptoms.
Reason other than EoE symptoms.
 Question 2: During any meal today, did food go down
slowly or get stuck in your throat or chest?
Yes.
No.
 Question 3: For the most difficult time you had
swallowing today, did you have to do anything to
make the food go down or to get relief?
If Question 3 is yes:‒ Yes, I had to drink liquid to get relief.
‒ Yes, I had to cough and or gag to get relief.
‒ Yes, I had to vomit to get relief.
‒ Yes, the stuck food had to be removed by a




 Question 4a: How would you rate your pain associ-
ated with swallowing food today?
Range 1 (minimal pain) – 10 (worst pain imaginable).
Subjects completed a daily symptom diary for at least
the last 2 weeks  3 days during the screening period
before day 1, and daily from day 1 through week 16. In
addition, subjects completed a daily symptom diary for




The esophageal mucosal endoscopic features of EoE
were assessed by each investigator using the EoE
Endoscopic Reference Score1 in 5 classification cate-
gories at screening, week 16, or if applicable at end of
treatment. Grades for each feature and total scores were
calculated for the following features: fixed rings:
0 (none), 1 (mild), 2 (moderate), or 3 (severe); exudates:
0 (none), 1 (mild), or 2 (severe); furrows: 0 (none) or 1
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0 (none) or 1 (present).
The EoE histology grade score was recorded inde-
pendently in the proximal, mid, and distal esophagus as
the sum of 8 features (basal zone hyperplasia, peak
eosinophil count, abscesses, surface layering, dilated
intercellular spaces, surface alteration, apoptotic epithe-
lial cells, and lamina propria fibrosis). A total possible
score was recorded based on features that were not
evaluable. Each of the locations was standardized to a
single score based on the following formula: adjusted
score ¼ (total score)/(total possible score) 100. The
EoE histology stage score, which was recorded for the
same 8 features, was calculated in the same manner.
Eosinophilic Esophagitis Endoscopic Histology
Grade and Stage Score
Esophageal eosinophil counts and other parameters
were assessed using the EoEHSS, a validated measure for
evaluating eosinophil density, basal zone hyperplasia,
eosinophil abscesses, eosinophil surface layering, dilated
intercellular spaces, surface epithelial alteration, dys-
keratotic epithelial cells, and lamina propria fibrosis.2
The esophageal histologic changes characteristic of
EoE were assessed by examining the following 8 pa-
rameters2: eosinophil inflammation was graded using the
peak eosinophil count, which was obtained by counting
eosinophils in the most densely inflamed hpf; basal zone
hyperplasia: more than 15% of the total epithelial
thickness; eosinophil abscess: solid mass of intra-
epithelial eosinophils; eosinophil surface layering: linear
alignment of eosinophils parallel to the epithelial surface;
dilated intracellular spaces: spaces around squamous
epithelial cells that show intercellular bridges; surface
epithelial alteration: surface epithelial cells that show
altered tinctorial properties, manifest as dark staining,
with or without intraepithelial eosinophils; dyskeratotic
epithelial cells: individual cells with deeply eosinophilic
cytoplasm and hyperchromatic nuclei; and lamina
propria fibers: thickened connective tissue fibers in the
lamina propria.
Each feature was scored separately for grade
(severity) or stage (extent) of abnormality using a 4-




Eosinophil counts. Forty-one of 86 subjects enrolled
in the LTE study were considered steroid-refractory;
results in the steroid-refractory subgroup were
similar to those in the overall study population. In both
steroid-status groups, reductions in the mean esopha-
geal eosinophil count from LTE baseline to LTE weeks12, 24, and 52 were observed for subjects who had
been randomized to placebo during the DB induction
portion of the study (Supplementary Figure 4A and B).
At LTE week 52, steroid-refractory subjects in the
placebo group showed a mean change in eosinophil
counts of -86.4; the RPC4046 180-mg and RPC4046
360-mg groups showed mean changes of -25.5 and
-4.0, respectively. The mean esophageal eosinophil
counts generally were similar across all 3 randomized
groups irrespective of steroid status starting at LTE
week 12 and continuing through LTE week 52. The
proportion of steroid-refractory subjects with a peak
eosinophil count less than 15/hpf decreased from LTE
week 12 (28.6% in the placebo, 41.7% in the RPC4046
180 mg, and 50.0% in the RPC4046 360 mg groups) to
LTE week 52 (21.4% in the placebo, 33.3% in the
RPC4046 180 mg, and 35.7% in the RPC4046 360 mg
groups); whereas, the proportion of non–steroid-re-
fractory subjects with a peak eosinophil count less
than 15/hpf increased overall from LTE week 12
(33.3% in the placebo, 62.5% in the RPC4046 180 mg,
and 38.5% in the RPC4046 360 mg groups) to LTE
week 52 (46.7% in the placebo, 43.8% in the RPC4046
180 mg, and 53.8% in the RPC4046 360 mg groups).
Daily symptom diary composite score and compo-
nents. The mean DSD composite scores among
non–steroid-refractory subjects were similar across all 3
groups at LTE baseline (placebo, 11.9; RPC4046 180 mg,
16.3; and RPC4046 360 mg, 14.7), and at each visit
starting at LTE week 12 through LTE week 52, with the
exception of the RPC4046 180-mg dose group at LTE
week 24, which was slightly higher. By LTE week 52, all
3 groups showed a decrease in mean DSD composite
scores (Supplementary Figure 4D). The mean DSD com-
posite scores among steroid-refractory subjects for the
placebo, RPC4046 180-mg, and RPC4046 360-mg groups
were 31.0, 24.3, and 12.6, respectively. Scores for all 3
groups decreased from LTE baseline to LTE week 52
(Supplementary Figure 4C).
Eosinophilic esophagitis endoscopic reference total
scores. Among steroid-refractory subjects, the mean
EREFS total score over all locations was higher at LTE
baseline in the placebo group vs the RPC4046 180-mg
and 360-mg groups (Supplementary Table 3). De-
creases in the mean EREFS total score over all locations
were observed from LTE baseline to each LTE visit
across all 3 treatment groups. By LTE week 52, the mean
EREFS total scores over all locations were similar in all 3
groups. Similarly, reductions for steroid-refractory sub-
jects from LTE baseline to similar mean values at LTE
week 52 also were noted across all 3 groups for the
inflammation composite score and for the exudates score
over all locations. For other EREFS scores of remodeling
composite score, fixed rings, furrows, edema, and stric-
ture over all locations, decreases from LTE baseline to
most post-LTE baseline visits were observed, but the
absolute mean values at week 52 varied across DB ran-
domized treatment groups (Supplementary Table 3).
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creases from LTE baseline to LTE week 52 in EREFS total
score and the majority of the component scores also
were observed across all 3 randomized treatment
groups. For the total score and component scores of the
inflammation composite score, remodeling composite
score, fixed rings, exudates, and edema, there were no
consistent trends.
Other efficacy end points. EEsAI scores were
similar between the steroid-refractory and non–steroid-
refractory subjects at week 52 LTE, with the exception of
the placebo group. Steroid-refractory and non–steroid-Supplementary Figure 1. Patient flow chart. DB, double-blind; E
open-label extension; PPI, proton pump inhibitor.refractory subjects continued to show improvement in
EEsAI patient-reported outcome scores during the DB
treatment period through week 52 of LTE.oE,Supplementary References
1. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of
the esophageal features of eosinophilic esophagitis: validation of
a novel classification and grading system. Gut 2013;62:489–495.
2. Collins MH, Martin LJ, Alexander ES, et al. Newly developed and
validated eosinophilic esophagitis histology scoring system and
evidence that it outperforms peak eosinophil count for disease
diagnosis and monitoring. Dis Esophagus 2017;30:1–8.eosinophilic esophagitis; LTE, long-term extension; OLE,
Supplementary Figure 2. Eosinophilic esophagitis endoscopic reference score (EREFS) total over all locations - total score
over time for each subject by treatment group (intention-to-treat population). EREFS total over all locations at double-blind
weeks 0 and 16 and long-term extension weeks 12, 24, and 52. Individual data from the (A) placebo group (n ¼ 34), (B)
RPC4046 180-mg group (n ¼ 31), and (C) RPC4046 360-mg group (n ¼ 34). OLE, open-label extension.
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Supplementary Figure 3. Symptom-based eosinophilic esophagitis activity index (EEsAI) over time for each subject by
treatment group (intention-to-treat population). EEsAI over all locations at double-blind weeks 0 and 16 and long-term
extension weeks 12, 24, and 52. Individual data from the (A) placebo group (n ¼ 34), (B) RPC4046 180-mg group (n ¼ 31),
and (C) RPC4046 360-mg group (n ¼ 34). OLE, open-label extension; PRO, patient-reported outcome.
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Supplementary Figure 4.Mean change (SEM) from long-term extension baseline in esophageal eosinophil counts and
composite diary scores by steroid-refractory status at long-term extension (LTE) weeks 12, 24, and 52. (A) Esophageal
eosinophil counts in the steroid-refractory group (eosinophils/high-power field [eos/hpf]), (B) Esophageal eosinophil counts in
the non–steroid-refractory group (eos/hpf). (C) Composite daily symptom diary (DSD) score in the steroid-refractory group. (D)
Composite DSD score in the non–steroid-refractory group (LTE population).
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Supplementary Table 1. Participants Across Study Sites by Country in the LTE Period in the LTE Population
Country Site
Double-Blind Randomized Treatment Group
Total (N ¼ 86), n (%)Placebo (n ¼ 29), n (%)
RPC4046 180 mg
(n ¼ 28), n (%)
RPC4046 360 mg



















102 4 (13.8) 3 (10.3) 4 (14.3) 3 (10.7) 3 (10.3) 2 (6.9) 11 (12.8) 8 (9.3)
104 1 (3.4) 1 (3.4) 2 (7.1) 2 (7.1) 4 (13.8) 2 (6.9) 7 (8.1) 5 (5.8)
106 2 (6.9) 2 (6.9) 3 (10.7) 2 (7.1) 2 (6.9) 2 (6.9) 7 (8.1) 6 (7.0)
107 4 (13.8) 4 (13.8) 0 0 0 0 4 (4.7) 4 (4.7)
112 1 (3.4) 0 3 (10.7) 3 (10.7) 0 0 4 (4.7) 3 (3.5)
115 1 (3.4) 0 1 (3.6) 1 (3.6) 0 0 2 (2.3) 1 (1.2)
116 0 0 2 (7.1) 2 (7.1) 3 (10.3) 3 (10.3) 5 (5.8) 5 (5.8)
118 0 0 1 (3.6) 1 (3.6) 1 (3.4) 0 2 (2.3) 1 (1.2)
121 0 0 0 0 1 (3.4) 1 (3.4) 1 (1.2) 1 (1.2)
122 1 (3.4) 1 (3.4) 0 0 0 0 1 (1.2) 1 (1.2)
124 0 0 0 0 1 (3.4) 1 (3.4) 1 (1.2) 1 (1.2)
125 1 (3.4) 1 (3.4) 0 0 3 (10.3) 3 (10.3) 4 (4.7) 4 (4.7)
130 1 (3.4) 0 2 (7.1) 2 (7.1) 0 0 3 (3.5) 2 (2.3)
132 0 0 1 (3.6) 1 (3.6) 0 0 1 (1.2) 1 (1.2)
133 1 (3.4) 1 (3.4) 0 0 0 0 1 (1.2) 1 (1.2)
135 1 (3.4) 0 0 0 0 0 1 (1.2) 0
136 1 (3.4) 1 (3.4) 1 (3.6) 0 1 (3.4) 1 (3.4) 3 (3.5) 2 (2.3)
139 0 0 0 0 2 (6.9) 1 (3.4) 2 (2.3) 1 (1.2)
141 0 0 1 (3.6) 1 (3.6) 0 0 1 (1.2) 1 (1.2)
143 4 (13.8) 3 (10.3) 1 (3.6) 1 (3.6) 1 (3.4) 1 (3.4) 6 (7.0) 5 (5.8)
144 2 (6.9) 1 (3.4) 1 (3.6) 1 (3.6) 4 (13.8) 2 (6.9) 7 (8.1) 4 (4.7)
145 1 (3.4) 1 (3.4) 1 (3.6) 1 (3.6) 4 (13.8) 2 (6.9) 7 (8.1) 4 (4.7)
146 0 0 1 (3.6) 0 1 (3.4) 1 (3.4) 2 (2.3) 1 (1.2)
147 1 (3.4) 1 (3.4) 0 0 0 0 1 (1.2) 1 (1.2)
148 0 0 0 0 1 (3.4) 0 1 (1.2) 0
Canada 202 1 (3.4) 0 0 0 0 0 1 (1.2) 0
Switzerland 301 1 (3.4) 1 (3.4) 2 (7.1) 2 (7.1) 0 0 3 (3.5) 3 (3.5)
302 0 0 0 0 1 (3.4) 1 (3.4) 1 (1.2) 1 (1.2)
NOTE. Dosed refers to the number of subjects receiving the study drug in the LTE period. Completed refers to the number of subjects completing the LTE period.
Percentages are used on the number of subjects dosed.
LTE, long-term extension.
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Supplementary Table 2. Change From Baseline in the Blood EOS: Observed Cases in the ITT and LTE Populations
Week 16
Visit Placebo (n ¼ 34) RPC4046 180 mg (n ¼ 31) RPC4046 360 mg (n ¼ 34)
ITT population
Baseline
N 34 31 34
Mean (SD) .44 (.232) .51 (.282) .39 (.191)
Median .4 .5 .35
Min, Max .1, 1.0 .1, 1.4 .1, .8
DB week 16
N 32 28 31
Mean (SD) .37 (.219) .45 (.291) .34 (.158)
Median .3 .45 .3
Min, Max 0, .9 0, 1.3 .1, .8
Change to DB week 16
N 32 28 31
Mean (SD) -.07 (.237) -.07 (.294) -.05 (.161)
Median 0 -.1 0
Min, Max -.8, .3 -.9, .8 -.5, .2
LSMD (RPC4046 - placebo) (SE) .045 (.051) -.01 (.050)
95% CI of LSMD -.06, .15 -.11, .09
P valuea .3864 .8341
Placebo (n ¼ 17) RPC4046 180 mg (n ¼ 26) RPC4046 360 mg (n ¼ 22)
ITT atopic subgroupb
Baseline
N 17 26 22
Mean (SD) .42 (.222) .53 (.280) .38 (.185)
Median .4 .5 .35
Min, Max .1, 1.0 .2, 1.4 .1, .8
DB week 16
N 15 24 21
Mean (SD) .41 (.222) .45 (.284) .32 (.137)
Median .4 .45 .3
Min, Max .1, .9 .1, 1.3 .1, .6
Change to DB week 16
N 15 24 21
Mean (SD) -.02 (.132) -.09 (.311) -.06 (.175)
Median 0 -.15 0
Min, Max -.2, .3 -.9, .8 -.5, .2
LSMD (RPC4046 - placebo) (SE) 0 (.063) -.05 (.064)
95% CI of LSMD -.12, .13 -.18, .08
P valuea .9480 .4600
continued on next page
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Supplementary Table 2. continued
Week 52
Placebo (n ¼ 29) RPC4046 180 mg (n ¼ 28) RPC4046 360 mg (n ¼ 29)
LTE population
Baseline
N 29 28 29
Mean (SD) .45 (.223) .52 (.283) .38 (.201)
Median .40 .50 .3
Min, Max .1, 1.0 .1, 1.4 .1, .8
LTE week 52
N 21 24 22
Mean (SD) .36 (.234) .48 (.446) .39 (.301)
Median .3 .4 .4
Min, Max .1, 1.1 .0, 2.1 .1, 1.4
Change to LTE week 52
N 21 24 22
Mean (SD) -.1 (.192) -.05 (.373) .03 (.307)
Median -.1 -.05 0
Min, Max -.5, .3 -.7, 1.2 -.3, 1.1
Placebo (n ¼ 14) RPC4046 180 mg (n ¼ 24) RPC4046 360 mg (n ¼ 20)
LTE atopic subgroup
Baseline
N 14 24 20
Mean (SD) .44 (.238) .53 (.278) .38 (.194)
Median .4 .5 .35
Min, Max .1, 1.0 .2, 1.4 .1, .8
LTE week 52
N 11 20 13
Mean (SD) .37 (.276) .42 (.292) .43 (.357)
Median .3 .4 .4
Min, Max .1, 1.1 .0, 1.4 .1, 1.4
Change to LTE week 52
N 11 20 13
Mean (SD) -.06 (.157) -.13 (.268) .08 (.377)
Median -.1 -.15 0
Min, Max 11 20 13
DB, double-blind; EOS, eosinophils; ITT, intent-to-treat; LSMD, least-squares mean difference; LTE, long-term extension; Max, maximum; Min, minimum.
aP values comparing RPC4046 with placebo are based on an analysis of covariance model with treatment group and actual steroid-refractory status as factors and
the baseline blood EOS as a covariate.
bThe atopic subgroup includes a medical history of atopic dermatitis, allergy, asthma, anaphylaxis, eczema, or nasal polyp.
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Supplementary Table 3. Inflammatory Component (Edema, Exudate, Furrows) and Stenosis (Fixed Rings, Stricture)
Component of EREFS for the Total Population and Steroid-Refractory Group in the LTE Period in the
LTE Population




180 mg (n ¼ 28)
RPC4046




180 mg (n ¼ 12)
RPC4046
360 mg (n ¼ 15)
Total score
Baselinea n ¼ 29 n ¼ 26 n ¼ 28 n ¼ 14 n ¼ 12 n ¼ 14
Mean (SD) 8.1 (5.1) 5.5 (3.8) 6.5 (4.4) 11.1 (4.7) 6.2 (4.7) 5.9 (4.0)
Week 52 n ¼ 21 n ¼ 24 n ¼ 22 n ¼ 10 n ¼ 10 n ¼ 13
Mean (SD) 3.0 (3.1) 4.6 (4.4) 3.0 (2.4) 4.1 (2.9) 4.6 (4.2) 3.1 (2.6)
Edema
Baselinea n ¼ 29 n ¼ 27 n ¼ 28 n ¼ 14 n ¼ 12 n ¼ 14
Mean (SD) 1.7 (1.4) 1.1 (1.3) 1.6 (1.3) 2.6 (0.9) 1.1 (1.4) 1.4 (1.2)
Week 52 n ¼ 21 n ¼ 24 n ¼ 22 n ¼ 10 n ¼ 10 n ¼ 13
Mean (SD) 0.9 (1.2) 0.8 (1.2) 0.8 (1.1) 1.5 (1.4) 0.4 (1.0) 0.8 (1.2)
Exudates
Baselinea n ¼ 29 n ¼ 26 n ¼ 28 n ¼ 14 n ¼ 12 n ¼ 14
Mean (SD) 1.3 (1.6) 0.7 (1.3) 1.0 (1.7) 2.0 (1.8) 0.7 (1.1) 1.1 (1.6)
Week 52 n ¼ 21 n ¼ 24 n ¼ 22 n ¼ 10 n ¼ 10 n ¼ 13
Mean (SD) 0.3 (0.9) 0.7 (1.3) 0.5 (0.9) 0.5 (1.1) 0.3 (1.0) 0.4 (0.9)
Furrows
Baselinea n ¼ 29 n ¼ 26 n ¼ 28 n ¼ 14 n ¼ 12 n ¼ 14
Mean (SD) 1.9 (1.1) 1.0 (1.2) 1.3 (1.2) 1.0 (1.3) 0.8 (0.1) 1.2 (1.3)
Week 52 n ¼ 21 n ¼ 24 n ¼ 22 n ¼ 10 n ¼ 10 n ¼ 13
Mean (SD) 0.4 (1.0) 0.6 (1.2) 0.8 (1.0) 0.2 (0.6) 0.8 (1.3) 0.8 (1.0)
Fixed rings
Baselinea n ¼ 29 n ¼ 27 n ¼ 28 n ¼ 14 n ¼ 12 n ¼ 14
Mean (SD) 2.6 (2.1) 2.4 (1.7) 2.3 (1.9) 1.5 (0.9) 2.3 (1.6) 1.1 (1.0)
Week 52 n ¼ 21 n ¼ 24 n ¼ 22 n ¼ 10 n ¼ 10 n ¼ 13
Mean (SD) 1.2 (1.5) 2.0 (1.7) 1.0 (1.0) 1.5 (0.9) 2.3 (1.6) 1.1 (1.0)
Stricture
Baselinea n ¼ 29 n ¼ 26 n ¼ 28 n ¼ 14 n ¼ 12 n ¼ 14
Mean (SD) 0.6 (0.9) 0.4 (0.9) 0.3 (0.5) 0.9 (1.1) 0.7 (1.2) 0.3 (0.5)
Week 52 n ¼ 21 n ¼ 24 n ¼ 22 n ¼ 10 n ¼ 10 n ¼ 13
Mean (SD) 0.2 (0.4) 0.5 (0.9) 0.0 (0.2) 0.4 (0.5) 0.8 (1.2) 0.1 (0.3)
EREFS, eosinophilic esophagitis endoscopic reference score; LTE, long-term extension.
aBaseline is defined as the last observed score before the first dose of study drug during the LTE.
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Supplementary Table 4. Remission in ITT Population: EEsAI PRO Score of 20 or Less
Visit Placebo (n ¼ 34), n/N (%) 180 mg (n ¼ 31), n/N (%); P value 360 mg, (n ¼ 34), n/N (%); P value
ITT population
Baseline 0/34 (0) 0/30 (0) 0/34 (0)
Week 16 4/34 (11.8) 7/31 (22.6); .2466 10/34 (29.4); .0767
LTE week 12 10/29 (34.5) 12/28 (42.9); .5038 15/27 (55.6); .1240
LTE week 24 14/29 (48.3) 10/28 (35.7); .3299 18/27 (66.7); .1651
LTE week 52 16/29 (55.2) 13/28 (46.4); .4921 18/27 (66.7); .3755
ITT atopic subgroup
Baseline 0/17 (0) 0/25 (0) 0/22 (0)
Week 16 2/17 (11.8) 7/26 (26.9); .2102 6/22 (27.3); .2850
LTE week 12 6/14 (42.9) 11/25 (44.0); .6931 10/18 (55.6); .4386
LTE week 24 7/14 (50.0) 9/24 (37.5); .5419 11/18 (61.1); .5867
LTE week 52 7/14 (50.0) 12/24 (50.0); .9436 11/18 (61.1); .4946
EEsAI, Eosinophilic Esophagitis Activity Index; ITT, intent to treat; LTE, long-term extension; PRO, patient-reported outcome.
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Supplementary Table 5.Mean Daily Symptom Diary Composite Score by Visit in the Open-Label Extension: Observed Cases in the LTE Population
Visit










LTE baseline, a n, mean
(SD)
21, 21.00 (18.554) 26, 20.01 (17.626) 24, 13.76 (16.767) 71, 18.19 (17.664)
LTE week 12, n, mean
(SD)
15, 14.94 (17.171) 13, -3.35 (5.750) 19, 9.60 (14.897) 19, -9.50 (15.286) 17, 9.03 (14.031) 17, -3.90 (8.596) 51, 10.98 (15.236) 49, -5.93 (11.349)
LTE week 24, n, mean
(SD)
14, 9.25 (14.137) 12, -6.54 (11.511) 13, 9.91 (16.169) 13, -7.82 (13.911) 15, 7.73 (12.751) 15, -6.35 (8.351) 42, 8.91 (14.010) 40, -6.89 (11.063)
LTE week 52, n, mean
(SD)
9, 7.11 (10.952) 8, -8.61 (10.732) 12, 6.67 (11.785) 11, -11.31 (12.481) 11, 4.35 (6.936) 11, -8.46 (11.569) 32, 5.99 (9.862) 30, -9.54 (11.382)
LTE week 60, n, mean
(SD)
6, 20.72 (13.924) 6, 2.76 (20.348) 5, 7.38 (16.506) 5, -10.68 (21.484) 10, 5.64 (7.463) 10, -6.95 (12.303) 21, 10.36 (13.175) 21, -5.06 (17.086)
LTE, long-term extension.



















Supplementary Table 6. Histologic Response Responder Analysis: Observed Cases in ITT and LTE Populations
Placebo RPC4046 180 mg RPC4046 360 mg Total RPC4046 Total
Atopic subgroup
Histologic response at
week 16 (ITT population)
0/16 12/24 (50.0) 9/20 (45.0) 21/44 (47.7) 21/60 (35.0)
Histologic response at LTE
week 52 (LTE population)
7/11 (63.6) 14/19 (73.7) 5/13 (38.5) 19/32 (59.4) 26/43 (60.5)
All subjects
Histologic response at
week 16 (ITT population)
0/29 14/28 (50.0) 15/29 (51.7) 29/57 (50.9) 29/86 (33.7)
Histologic response at LTE
week 52 (LTE population)
12/21 (57.1) 17/23 (73.9) 13/22 (59.1) 30/45 (66.7) 42/66 (63.6)
ITT, intent-to-treat; LTE, long-term extension.
Supplementary Table 7. EREFS Total Over All Locations in the ITT Population
Visit
Placebo (n ¼ 17, DB
period; ¼ 14, LTE period)
RPC4046 180 mg (n ¼ 26,
DB period; ¼ 24, LTE period)
RPC4046 360 mg (n ¼ 22,









Baseline, n, mean (SD) 32, 9.13 (4.301) 27, 8.96 (4.345) 31, 9.39 (4.287)
Week 16, n, mean (SD) 32, 7.94 (5.136) 30, -0.9 (3.863) 27, 5.30 (4.168) 24, -4.17 (3.306) 30, 4.80 (3.388) 27, -4.81 (4.086)
LTE week 12, n, mean (SD) 29, 4.93 (4.053) 27, -4.11 (4.492) 28, 4.29 (3.943) 24, -5.71 (3.495) 27, 4.04 (3.777) 24, -5.13 (4.730)
LTE week 24, n, mean (SD) 29, 4.28 (4.157) 27, -4.85 (3.949) 28, 4.14 (3.808) 24, -5.75 (2.938) 27, 4.00 (3.258) 24, -5.38 (4.604)
LTE week 52, n, mean (SD) 29, 3.66 (3.754) 27, -5.37 (4.208) 28, 4.57 (4.246) 24, -5.21 (3.134) 27, 3.26 (2.551) 24, -6.17 (4.584)
ITT atopic subgroup
Baseline, n, mean (SD) 16, 9.75 (4.313) 24, 9.63 (4.052) 21, 8.67 (3.706)
Week 16, n, mean (SD) 15, 10.13 (5.579) 14, 0.5 (4.274) 24, 5.71 (4.175) 22, -4.23 (3.366) 21, 4.86 (3.623) 20, -3.9 (3.210)
LTE week 12, n, mean (SD) 14, 6.64 (3.973) 13, -3.23 (4.475) 24, 4.04 (3.495) 22, -5.91 (3.504) 18, 4.44 (4.232) 17, -3.76 (4.191)
LTE week 24, n, mean (SD) 14, 5.43 (4.669) 13, -4.62 (3.948) 24, 3.83 (3.293) 22, -6.05 (2.853) 18, 4.06 (3.455) 17, -4.47 (4.170)
LTE week 52, n, mean (SD) 14, 4.5 (4.274) 13, -5.31 (4.644) 24, 4.21 (3.647) 22, -5.41 (3.142) 18, 3.67 (2.808) 17, -4.76 (3.456)
DB, double-blind; EREFS, eosinophilic esophagitis endoscopic reference score; ITT, intent-to-treat; LTE, long-term extension.
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Supplementary Table 8. Treatment-Emergent Serious
Adverse Events by Preferred Term














Patients with a serious
adverse event
0 2 (7.1) 4 (13.8) 6 (7.0)
Acute cholecystitis 0 1 0 1
Spontaneous
abortion
0 0 1 1
Asthma 0 1 0 1
Diverticulitis 0 0 1 1
Schizophreniab 0 0 1 1
Femur fracture 0 0 1 1
NOTE. Data shown are number or number (%).
LTE, long-term extension.
aThe definition of a serious adverse event is any untoward medical occurrence
that results in death, is life-threatening (has an immediate risk of death), re-
quires admission to a hospital or prolongation of an existing hospitalization,
results in persistent or significant disability or incapacity, or results in a
congenital anomaly or birth defect.
bThis treatment-emergent adverse event led to discontinuation of the study
drug and withdrawal from the study.
Supplementary Table 9. Injection Site Treatment-Emergent














3 (10.3) 6 (21.4) 7 (24.1) 16 (18.6)
Injection site erythema 1 (3.4) 1 (3.6) 2 (6.9) 4 (4.7)
Injection site hematoma 1 (3.4) 1 (3.6) 2 (6.9) 4 (4.7)
NOTE. Data are shown as number (%).
LTE, long-term extension; TEAE, treatment-emergent adverse event.
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